Get started
Author

Marek Dudziński

Observed names: Dudziński, Marek, M. Dudziński, MAREK DUDZINSKI, Marek Dudzinski
Observed institutions: Inserm, German Cancer Research Center, Klinikum Itzehoe, Copernicus Memorial Hospital, Medical University of Lodz, Centre de Recherche en Cancérologie de Lyon, Shizuoka Red Cross Hospital, The Sixth People's Hospital of Zhengzhou, Universitat de Barcelona, University of Rzeszów
ORCID: 0000-0001-5197-0785
Observed ORCID: 0000-0001-5197-0785
OpenAlex ID: A5031565632
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
2019 · Maroulio Pertesi, Maxime Vallée, et al. · Leukemia · 48
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients
2015 · Elad Ziv, Eric Dean, et al. · Nature Communications · 43
PDF
Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length
2014 · Daniele Campa, Alessandro Martino, et al. · International Journal of Cancer · 40
Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)
2017 · Elżbieta Iskierka-Jażdżewska, Marek Hus, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 39
Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome
2011 · Grzegorz Helbig, Marek Hus, et al. · Medical Oncology · 28
A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry
2017 · Tomasz Sacha, Joanna Góra‐Tybor, et al. · American Journal of Hematology · 27
PDF
Genetically determined telomere length and multiple myeloma risk and outcome
2021 · Matteo Giaccherini, Angelica Macauda, et al. · Blood Cancer Journal · 20
Supporting the Diagnosis of Fabry Disease Using a Natural Language Processing-Based Approach
2023 · Adrian A. Michalski, Karol Lis, et al. · Journal of Clinical Medicine · 19
PDF
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
2023 · Esther Clavero, José Manuel Sanchez-Maldonado, et al. · International Journal of Molecular Sciences · 18
Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations—An Extensive Replication of the Associations from the Candidate Gene Era
2014 · Alessandro Martino, Daniele Campa, et al. · Cancer Epidemiology Biomarkers & Prevention · 18
Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study
2020 · BARTOSZ PULA, ELZBIETA ISKIERKA-JAZDZEWSKA, et al. · Anticancer Research · 17
PDF
Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients
2018 · Angelica Macauda, Eleonora Castelli, et al. · British Journal of Haematology · 17
PDF
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study
2019 · Daniele Campa, Alessandro Martino, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 13
Identification of novel genetic loci for risk of multiple myeloma by functional annotation
2023 · Angelica Macauda, Klara Briem, et al. · Leukemia · 12
PDF
A polygenic risk score for multiple myeloma risk prediction
2021 · Federico Canzian, Chiara Piredda, et al. · European Journal of Human Genetics · 12
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
2021 · Angelica Macauda, Chiara Piredda, et al. · International Journal of Cancer · 12
Identification of miRSNPs associated with the risk of multiple myeloma
2016 · Angelica Macauda, Diego Calvetti, et al. · International Journal of Cancer · 12
PDF
Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium
2019 · Elżbieta Iskierka-Jażdżewska, Federico Canzian, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 10
Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities – Polish Adult Leukemia Group (PALG) real-life analysis
2018 · Monika Długosz-Danecka, Wojciech Jurczak, et al. · Polskie Archiwum Medycyny Wewnętrznej · 10
PDF
Impact of genetic polymorphisms of drug transporters ABCB1 and ABCG2 and regulators of xenobiotic transport and metabolism PXR and CAR on clinical efficacy of dasatinib in chronic myeloid leukemia
2022 · Anna Marta Madejczyk, Federico Canzian, et al. · Frontiers in Oncology · 9
PDF
Multifocal Pyoderma Gangrenosum with an Underlying Hemophagocytic Lymphohistiocytosis: Case Report and the Review of the Literature
2021 · Aleksandra Opalińska, Dominika Kwiatkowska, et al. · Dermatology and Therapy · 6
PDF
Cereblon (CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium
2014 · Elzbieta Iskierka-Jazdzewska, Anna Stepien, et al. · Blood · 6
Common gene variants within 3′‐untranslated regions as modulators of multiple myeloma risk and survival
2020 · Ombretta Melaiu, Angelica Macauda, et al. · International Journal of Cancer · 5
PDF
Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?
2022 · Angelica Macauda, Alyssa Clay-Gilmour, et al. · Cancer Epidemiology Biomarkers & Prevention · 3
Praktyka kliniczna oceny minimalnej choroby resztkowej u chorych na szpiczaka plazmocytowego w Polsce: badanie ankietowe Polskiego Konsorcjum Szpiczakowego
2018 · Agnieszka Krzywdzińska, Iwona Solarska, et al. · Hematologia · 3
PDF
Works count: 54
Citation count: 469
H-index: 13
I10-index: 19
Year
Topic
Type